Select therapeutic use:

Bone and connective tissue cancer:

Indications for TAZVERIK:

Metastatic or locally advanced epithelioid sarcoma in patients not eligible for complete resection.

Adult:

Swallow whole. ≥16yrs: 800mg twice daily; continue until disease progression or unacceptable toxicity. Dose modifications for adverse reactions or for drug interactions: see full labeling.

Children:

<16yrs: not established.

Warnings/Precautions:

Increased risk of secondary malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, T-cell lymphoblastic lymphoma). Embryo-fetal toxicity. Advise to use effective contraception (non-hormonal) during and for 6 months (females of reproductive potential) and for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Pharmacologic Class:

Methyltransferase inhibitor.

Interactions:

May be potentiated by strong or moderate CYP3A inhibitors; avoid. If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce dose (see full labeling). May be antagonized by strong or moderate CYP3A inducers; avoid. May antagonize CYP3A substrates, including hormonal contraceptives.

Adverse Reactions:

Pain, fatigue, nausea, decreased appetite, vomiting, constipation, upper RTI, musculoskeletal pain, abdominal pain; lab abnormalities.

Generic Availability:

NO

How Supplied:

Tabs—240

Pricing for TAZVERIK

200mg tablet (Qty: 30)
Appx. price $1986
GoodRx

Leukemias, lymphomas, and other hematologic cancers:

Indications for TAZVERIK:

Relapsed or refractory follicular lymphoma in patients whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, or in patients with no satisfactory alternative treatment options.

Adult:

Confirm presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens. Swallow whole. ≥16yrs: 800mg twice daily; continue until disease progression or unacceptable toxicity. Dose modifications for adverse reactions or for drug interactions: see full labeling.

Children:

<16yrs: not established.

Warnings/Precautions:

Increased risk of secondary malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, T-cell lymphoblastic lymphoma). Embryo-fetal toxicity. Advise to use effective contraception (non-hormonal) during and for 6 months (females of reproductive potential) and for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Pharmacologic Class:

Methyltransferase inhibitor.

Interactions:

May be potentiated by strong or moderate CYP3A inhibitors; avoid. If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce dose (see full labeling). May be antagonized by strong or moderate CYP3A inducers; avoid. May antagonize CYP3A substrates, including hormonal contraceptives.

Adverse Reactions:

Pain, fatigue, nausea, decreased appetite, vomiting, constipation, upper RTI, musculoskeletal pain, abdominal pain; lab abnormalities.

Generic Availability:

NO

How Supplied:

Tabs—240

Pricing for TAZVERIK

200mg tablet (Qty: 30)
Appx. price $1986
GoodRx